Wilfried Ernst Erich Eberhardt

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/9941698/publications.pdf

Version: 2025-02-01

110 peer-reviewed articles	18,733 peer-reviewed citations	68355 43 peer-reviewed h-index	277911 4.85 score
136 documents	22564 doc citations	65478 47 h-index	41371 citing authors

#	Article	IF	Citations
1	Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE). International Journal of Cancer, 2025, 156, 154-163.	2.8	5
2	Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome. International Journal of Cancer, 2025, 156, 776-787.	2.8	14
3	Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. Lancet Respiratory Medicine,the, 2025, 13, 887-896.	15.9	11
4	Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315). JTO Clinical and Research Reports, 2024, 5, 100626.	0.6	1
5	The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2024, 19, 1310-1325.	1.5	36
6	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2024, 19, 1052-1072.	1.5	46
7	The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need?. Cancers, 2024, 16, 1917.	2.7	1
8	IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2023, 18, 564-575.	1.5	138
9	SUVmaxAbove 20 in18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary. Journal of Nuclear Medicine, 2023, 64, 1191-1194.	4.0	9
10	Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie, 2023, 77, 671-813.	0.2	7
11	Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment. European Journal of Cardio-thoracic Surgery, 2022, 61, 269-276.	1.2	15
12	The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2022, 17, 838-851.	1.5	22
13	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. Lung Cancer, 2022, 168, 10-20.	1.8	18
14	Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen Lungenkarzinoms. Die Innere Medizin, 2022, 63, 717-723.	0.2	1
15	Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations. Clinical Lung Cancer, 2021, 22, e668-e672.	2.1	6
16	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	1.8	87
17	Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2894-2903.	4.0	24
18	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer, 2021, 149, 211-221.	2.8	19

#	Article	IF	Citations
19	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. EJNMMI Research, 2021, 11, .	1.6	7
20	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, .	2.1	2
21	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Lung Cancer, 2020, 139, 165-168.	1.8	6
22	Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. European Journal of Cancer, 2020, 138, 156-168.	2.8	6
23	Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1439-1447.	4.0	11
24	Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. ESMO Open, 2019, 4, e000577.	3.2	40
25	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochemical and Biophysical Research Communications, 2018, 500, 621-625.	1.5	48
26	MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clinical Lung Cancer, 2018, 19, e441-e463.	2.1	77
27	Clinical implications of the innovations in the primary tumour and metastasis of the 8th edition of the TNM classification for lung cancer. Journal of Thoracic Disease, 2018, 10, S2682-S2685.	0.9	17
28	Aktueller Stand der Diagnostik und Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) im Stadium III. Onkologe, 2018, 24, 974-982.	0.1	0
29	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	1.5	168
30	Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer, 2018, 18, .	2.1	15
31	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1109-1121.	1.5	455
32	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 54-64.	1.5	71
33	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. Onkologe, 2017, 23, 838-844.	0.1	0
34	Immuntherapie thorakaler Tumoren. Info Onkologie, 2017, 20, 21-27.	0.0	0
35	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2089-2099.	1.5	173
36	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2112-2119.	1.5	205

#	Article	IF	Citations
37	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2100-2111.	1.5	143
38	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. Journal of Thoracic Oncology, 2016, 11, 2082-2088.	1.5	75
39	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1433-1446.	1.5	248
40	Subgruppenanalyse aus der nicht-interventionellen Beobachtungsstudie REASON: PFS und OS gemäß Alter, Raucherstatus, Geschlecht und histologischem Subtyp unter Verwendung von Gefitinib bzw. chemotherapeutischer Behandlung bei NSCLC-Patienten. Pneumologie, 2016, 70, 579-588.	0.2	1
41	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1204-1223.	1.5	670
42	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 300-311.	1.5	425
43	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Journal of Thoracic Oncology, 2016, 11, 85-93.	1.5	31
44	Reply to the Letter to the Editor by Hendriks et al.. Journal of Thoracic Oncology, 2016, 11, e43-e44.	1.5	0
45	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 666-680.	1.5	209
46	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 651-665.	1.5	261
47	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 639-650.	1.5	236
48	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 681-692.	1.5	122
49	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 39-51.	1.5	4,297
50	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135.	26.4	8,158
51	Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer, 2015, 15, .	2.1	31
52	The IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology, 2015, 10, 1515-1522.	1.5	400
53	EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	0.6	39
54	Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. British Journal of Cancer, 2015, 113, 12-19.	4.1	168

#	Article	IF	Citations
55	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	8.0	374
56	Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 447-456.	16.1	203
57	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2015, 142, 795-805.	1.8	43
58	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	8.0	225
59	Systemic treatment of malignant pleural mesothelioma. Current Opinion in Oncology, 2014, 26, 171-181.	1.3	24
60	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	8.0	266
61	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 59-68.	16.1	520
62	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	8.0	480
63	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	4.5	69
64	Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2014, 15, 320-330.e3.	2.1	15
65	ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2013, 14, 558-567.e3.	2.1	43
66	10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL). Lung Cancer, 2013, 82, 83-89.	1.8	25
67	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	1.8	30
68	Midterm Changes in Quality of Life: A Prospective Evaluation After Open Pulmonary Metastasectomy. Annals of Thoracic Surgery, 2013, 95, 1006-1011.	2.6	16
69	Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer. European Journal of Cancer, 2013, 49, 2461-2468.	2.8	7
70	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. European Journal of Cancer, 2013, 49, 3076-3082.	2.8	26
71	Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. Onkologe, 2013, 19, 821-834.	0.1	0
72	Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma. Frontiers in Immunology, 2013, 4, .	3.3	33

#	Article	IF	Citations
73	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	1.5	117
74	Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed. Journal of Thoracic Oncology, 2013, 8, 19-30.	1.5	85
75	Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer. Investigational New Drugs, 2013, 32, 123-134.	1.6	6
76	Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology. Interactive Cardiovascular and Thoracic Surgery, 2012, 15, 612-617.	0.8	26
77	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 4794-4805.	4.5	69
78	Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology, 2012, 23, 678-687.	8.0	26
79	Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1440-1448.	1.5	38
80	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2012, 13, 33-42.	16.1	557
81	Inhibiting the Aurora B Kinase Potently Suppresses Repopulation During Fractionated Irradiation of Human Lung Cancer Cell Lines. International Journal of Radiation Oncology Biology Physics, 2012, 84, 492-499.	1.3	29
82	“One-stop-shop” staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases?. European Journal of Radiology, 2011, 78, 430-435.	2.1	42
83	First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncology, The, 2011, 12, 30-37.	16.1	118
84	Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Onkologe, 2011, 17, 691-701.	0.1	1
85	A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Annals of Oncology, 2011, 22, 1798-1804.	8.0	95
86	Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Investigational New Drugs, 2011, 30, 1962-1971.	1.6	17
87	Intensified High-Dose Chemoradiotherapy With Induction Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer—Safety and Toxicity Results Within a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2010, 76, 809-815.	1.3	21
88	Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1424-1430.	2.2	130
89	Prognostic relevance of soluble human leukocyte antigen–G and total human leukocyte antigen class I molecules in lung cancer patients. Human Immunology, 2010, 71, 489-495.	0.5	61
90	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2010, 11, 619-626.	16.1	412

#	Article	IF	Citations
91	Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel. Journal of Thoracic Oncology, 2009, 4, 1280-1288.	1.5	61
92	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, The, 2009, 373, 1525-1531.	46.9	1,356
93	Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 1036-1041.	2.2	47
94	Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 5407-5415.	12.4	218
95	Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer. European Radiology, 2008, 19, 193-200.	3.0	31
96	Prophylactic Cranial Irradiation in Operable Stage IIIA Non–Small-Cell Lung Cancer Treated With Neoadjuvant Chemoradiotherapy: Results From a German Multicenter Randomized Trial. Journal of Clinical Oncology, 2007, 25, 4987-4992.	12.4	138
97	P1-137: Novel strategies in molecular targeted therapy of mesothelioma. Journal of Thoracic Oncology, 2007, 2, S605.	1.5	0
98	Chemoradiation paradigm for the treatment of lung cancer. Nature Clinical Practice Oncology, 2006, 3, 188-199.	6.6	32
99	A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 2005, 50, 91-96.	1.8	45
100	The Role of Surgery in Stage IIIA Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 303-319.	1.5	4
101	Prophylactic cranial irradiation in lung cancer. Current Treatment Options in Oncology, 2004, 5, 43-50.	3.0	19
102	P-239 Optimizing chemoradiation (CTx/RTx) with epoetin-alpha support: Phase-II trial of induction CTx followed by concurrent CTx/RTx +/- surgery (S) in locally far advanced non-small-cell lung cancer stages IIIA and IIIB (LAD-NSCLC). Lung Cancer, 2003, 41, S152.	1.8	0
103	New Approaches for Small-Cell Lung Cancer: Local Treatments. Cancer Control, 2003, 10, 289-296.	1.5	21
104	Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. European Journal of Cardio-thoracic Surgery, 2002, 22, 292-297.	1.2	112
105	Lung cancer: Combined modality therapy in NSCLC. Annals of Oncology, 2000, 11, 85-96.	8.0	12
106	Title is missing!. Cancer and Metastasis Reviews, 1999, 18, 151-172.	6.8	1
107	Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Annals of Thoracic Surgery, 1999, 68, 1144-1149.	2.6	85
108	Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer. European Journal of Cancer, 0, 230, 116011.	2.8	2

#	Article	IF	Citations
109	Prognostic Value of Fibroblast Activation Protein–Directed PET Imaging in Pleural Mesothelioma. Journal of Nuclear Medicine, 0, 67, 383-390.	4.0	0
110	Real-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC. Cancers, 0, 18, 1754.	2.7	0